Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor

Antoinette R. Tan, Xiaowei Yang, Stephen M. Hewitt, Arlene Berman, Erin R. Lepper, Alex Sparreboom, Allyson L. Parr, William D. Figg, Catherine Chow, Seth M. Steinberg, Stephen L. Bacharach, Millie Whatley, Jorge A. Carrasquillo, Jaime S. Brahim, Seth A. Ettenberg, Stan Lipkowitz, Sandra M. Swain*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

164 Scopus citations

Fingerprint

Dive into the research topics of 'Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor'. Together they form a unique fingerprint.

Medicine & Life Sciences